This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

    More

    Page   1/2   
  • China senior housing — Now and the future
    Exploring the opportunities and risks of investment in China's senior housing market and the trends likely to be seen in the near future
  • Fortune favors the bold: Unlocking the future of China’s pharmaceutical market
    Exploring the key events of the past 24 months in China's health care market and four key themes pharmaceutical companies should consider as they think about their future in China.
  • Insider analysis from Monitor Deloitte on new commercial models For China’s tier 2 market
    Growth and margins are slowing or declining in the top tier market. Expanding into the geographically dispersed and fragmented Tier 2 market and serving the market cost effectively are top agenda for MNCs.
  • Top JV Issues for Pharmaceutical Companies in China
    Establishing a joint venture in China is a complex and time-consuming task, and there is no guarantee of success or even survival. It is critical for pharma executives to fully understand various pitfalls and manage the partnership for success.
  • 2014 Global Health Care Outlook
    The report examines the current state of the global health care sector.
  • 2014 Global Life Sciences Outlook
    The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
  • Corruption risk in the Chinese Pharmaceutical market
    The report illustrates the issues and challenges you may face as this situation unfolds, and the importance of having a strategy to address potential problems.
  • Transforming Medical Affairs in China
    Rethinking the role and effectiveness of the Medical Affairs function has become an urgent priority for pharmaceutical companies in China. The report presents our perspective on these challenges and how they can be successfully overcome.
  • Health care reform and life sciences: Threat, opportunity or both?
    Exploring how nearly 300 senior life science executives are meeting the challenges and opportunities of global health care reforms, and the national differences through case studies of China, Brazil and Germany.
  • The next phase: Opportunities in China's pharmaceuticals market
    This report focuses in particular on pharmaceuticals companies, both domestic and foreign, and their activities in the China market—all from the viewpoint of prospective investors.
  • Page   1/2   
Share your comments

 

Stay connected